The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib

Journal of Immunology

Volumn 185, Issue 9, 2010, Pages 5637-5647

  Lang, Veronika R ^a   Mielenz, Dirk ^a   Neubert, Kirsten ^a   Bohm, Christina ^a   Schett, Georg ^a   Jack, Hans Martin ^a   Voll, Reinhard E ^a   Meister, Silke ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEINASE INHIBITION; SIGNAL TRANSDUCTION; T CELL DEPLETION; T LYMPHOCYTE; UNFOLDED PROTEIN RESPONSE; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOBLOTTING; IMMUNOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; BORONIC ACIDS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOBLOTTING; MICE; MICE, INBRED BALB C; PLASMA CELLS; PROTEASE INHIBITORS; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN;

EID: 78149491863     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001040     Document Type: Article

References (36)

1. Schwartz, R. N., and M. Vozniak. 2008. Current and emerging treatments for multiple myeloma. J. Manag. Care Pharm. 14 (7, Suppl) 12-19.
2. Ludwig, H., D. Khayat, G. Giaccone, and T. Facon. 2005. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104:1794-1807.
3. Adams, J. 2004. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4:349-360.
4. Sunwoo, J. B., Z. Chen, G. Dong, N. Yeh, C. Crowl Bancroft, E. Sausville, J. Adams, P. Elliott, and C. Van Waes. 2001. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7:1419-1428.
5. Neubert, K., S. Meister, K. Moser, F. Weisel, D. Maseda, K. Amann, C. Wiethe, T. H. Winkler, J. R. Kalden, R. A. Manz, and R. E. Voll. 2008. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14:748-755.
6. Meister, S., U. Schubert, K. Neubert, K. Herrmann, R. Burger, M. Gramatzki, S. Hahn, S. Schreiber, S. Wilhelm, M. Herrmann, et al. 2007. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67:1783-1792.
7. Obeng, E. A., L. M. Carlson, D. M. Gutman, W. J. Harrington, Jr., K. P. Lee, and L. H. Boise. 2006. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107:4907-4916.
8. Fribley, A., and C. Y. Wang. 2006. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol. Ther. 5:745-748.
9. Mateos, M. V., and J. F. San Miguel. 2007. Bortezomib in multiple myeloma. Best Pract. Res. Clin. Haematol. 20:701-715.
10. Pillai, S., A. Cariappa, and S. T. Moran. 2005. Marginal zone B cells. Annu. Rev. Immunol. 23:161-196.
11. Martin, F., A. M. Oliver, and J. F. Kearney. 2001. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 14:617-629.
12. Zandvoort, A., and W. Timens. 2002. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin. Exp. Immunol. 130:4-11.
13. Maseda, D., S. Meister, K. Neubert, M. Herrmann, and R. E. Voll. 2008. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Cell Death Differ. 15:600-612.
14. Cascio, P., L. Oliva, F. Cerruti, E. Mariani, E. Pasqualetto, S. Cenci, and R. Sitia. 2008. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur. J. Immunol. 38:658-667.
15. Kloetzel, P. M. 2004. The proteasome and MHC class I antigen processing. Biochim. Biophys. Acta 1695:225-233.
16. Altun, M., P. J. Galardy, R. Shringarpure, T. Hideshima, R. LeBlanc, K. C. Anderson, H. L. Ploegh, and B. M. Kessler. 2005. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res. 65:7896-7901.
17. Busse, A., M. Kraus, I. K. Na, A. Rietz, C. Scheibenbogen, C. Driessen, I. W. Blau, E. Thiel, and U. Keilholz. 2008. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer 112:659-670.
18. Gething, M. J. 1999. Role and regulation of the ER chaperone BiP. Semin. Cell Dev. Biol. 10:465-472.
19. Zinszner, H., M. Kuroda, X. Wang, N. Batchvarova, R. T. Lightfoot, H. Remotti, J. L. Stevens, and D. Ron. 1998. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 12:982-995.
20. Masciarelli, S., A. M. Fra, N. Pengo, M. Bertolotti, S. Cenci, C. Fagioli, D. Ron, L. M. Hendershot, and R. Sitia. 2010. CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells. Mol. Immunol. 47:1356-1365.
21. Fennell, D. A., A. Chacko, and L. Mutti. 2008. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27:1189-1197.
22. Gong, Q., Q. Ou, S. Ye, W. P. Lee, J. Cornelius, L. Diehl, W. Y. Lin, Z. Hu, Y. Lu, Y. Chen, et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174:817-826.
23. Zinser, E., S. Rössner, L. Littmann, D. Lüftenegger, U. Schubert, and A. Steinkasserer. 2009. Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo. Immunobiology 214:843-851.
24. + T cells. Immunology 124:234-246.
25. Lopes-Carvalho, T., and J. F. Kearney. 2004. Development and selection of marginal zone B cells. Immunol. Rev. 197:192-205.
26. Hsu, M. C., K. M. Toellner, C. G. Vinuesa, and I. C. Maclennan. 2006. B cell clones that sustain long-term plasmablast growth in T-independent extrafollicular antibody responses. Proc. Natl. Acad. Sci. USA 103:5905-5910.
27. Bianchi, G., L. Oliva, P. Cascio, N. Pengo, F. Fontana, F. Cerruti, A. Orsi, E. Pasqualetto, A. Mezghrani, V. Calbi, et al. 2009. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113:3040-3049.
28. Gunn, K. E., and J. W. Brewer. 2006. Evidence that marginal zone B cells possess an enhanced secretory apparatus and exhibit superior secretory activity. J. Immunol. 177:3791-3798.
29. Ruckrich, T., M. Kraus, J. Gogel, A. Beck, H. Ovaa, M. Verdoes, H. S. Overkleeft, H. Kalbacher, and C. Driessen. 2009. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 23:1098-1105.
30. Weih, D. S., Z. B. Yilmaz, and F. Weih. 2001. Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines. J. Immunol. 167:1909-1919.
31. Allen, C., K. Saigal, L. Nottingham, P. Arun, Z. Chen, and C. Van Waes. 2008. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-κB subunits in head and neck cancer. Clin. Cancer Res. 14:4175-4185.
32. Voll, R., and F. Hiepe. 2009. Depletion of plasma cells: a novel strategy in the therapy of systemic lupus erythematosus in mice and man. Z. Rheumatol. 68:150-153.
33. Sun, K., M. Li, T. J. Sayers, L. A. Welniak, and W. J. Murphy. 2008. Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. Blood 112:1522-1529.
34. Everly, M. J., J. J. Everly, B. Susskind, P. Brailey, L. J. Arend, R. R. Alloway, P. Roy-Chaudhury, A. Govil, G. Mogilishetty, A. H. Rike, et al. 2009. Proteasome inhibition reduces donor-specific antibody levels. Transplant. Proc. 41:105-107.
35. Sun, K., D. E. Wilkins, M. R. Anver, T. J. Sayers, A. Panoskaltsis-Mortari, B. R. Blazar, L. A. Welniak, and W. J. Murphy. 2005. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 106:3293-3299.
36. Zandvoort, A., M. E. Lodewijk, P. A. Klok, P. M. Dammers, F. G. Kroese, and W. Timens. 2001. Slow recovery of follicular B cells and marginal zone B cells after chemotherapy: implications for humoral immunity. Clin. Exp. Immunol. 124:172-179.